Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference

Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch
                         2013 Health Care Conference

PR Newswire

CHESTERBROOK, Pa., May 10, 2013

CHESTERBROOK, Pa., May 10, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc.
(Nasdaq: AUXL) today announced that executive management will participate in
the Bank of America Merrill Lynch 2013 Health Care Conference to be held May
14-16 at the Encore at the Wynn Las Vegas. Mr. Adrian Adams, Chief Executive
Officer and President, is scheduled to present an overview of the Company and
its product pipeline at 3:00 p.m. PT (6:00 pm ET) on Wednesday, May 15,

(Logo: )

The presentation will also be webcast on the "For Investors" section of the
Auxilium website under the "Events" tab on May 15, 2013. To access the live
webcast, please log on to Auxilium's website approximately fifteen minutes
prior to the presentation to register and download any necessary audio
software. The presentation replay will be available for ninety days after the

About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a
focus on developing and marketing products to predominantly specialist
audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical
treatment of hypogonadism in the U.S., XIAFLEX® (collagenase clostridium
histolyticum (CCH)) for the treatment of adult Dupuytren's contracture
patients with a palpable cord in the U.S., and distributes XIAPEX® (the EU
tradename for CCH) in the European Union through Pfizer Inc. under a
transition services agreement until the applicable marketing authorizations
are fully transferred to Auxilium. GlaxoSmithKline LLC co-promotes Testim
with Auxilium in the U.S. Ferring International Center S.A. markets Testim in
certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.
Asahi Kasei Pharma Corporation has development and commercial rights for
XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and
commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. As a
result of its recent acquisition of Actient Holdings, LLC, Auxilium now
markets TESTOPEL®, the only long-acting implantable testosterone replacement
therapy, Edex®, the leading branded non-oral drug for erectile dysfunction,
Striant®, a buccal system for testosterone delivery, and Osbon ErecAid®, a
device for aiding erectile dysfunction, and also has a non-promoted
respiratory franchise, including Theo-24® and Semprex®-D, along with three
other non-promoted products. Auxilium has three projects in clinical
development. XIAFLEX is in phase III of development for the treatment of
Peyronie's disease. CCH is in phase IIa of development for the treatment of
Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for
the treatment of cellulite (edematous fibrosclerotic panniculopathy).
Auxilium also has rights to pursue additional indications for XIAFLEX. For
additional information, visit


This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995, including statements made
with respect to Auxilium's strategy, progress and timing of development
programs and related trials, the efficacy of its product candidates, the
commercial benefits available to it as a result of its agreements with third
parties, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management and other statements
regarding matters that are not historical facts, and involve predictions.
These statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or prospects
to be materially different from any future results, performance, achievements
or prospects expressed in or implied by such forward-looking statements. In
some cases you can identify forward-looking statements by terminology such as
''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'',
''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of
these terms or similar expressions, although not all forward-looking
statements contain these identifying words. Although forward-looking
statements are based on Auxilium's current plans or assessments that are
believed to be reasonable as of the date of this press release, they
inherently involve certain risks and uncertainties. These forward-looking
statements are subject to a number of risks and uncertainties, including those
discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for
the year ended December 31, 2012 and in other public filings with the SEC,
including, without limitation, as such Form 10-K was updated in Item 8.01 of
the Current Report on Form 8-K filed on April 29, 2013. While Auxilium may
elect to update the forward-looking statements made in this news release in
the future, Auxilium specifically disclaims any obligation to do so.
Auxilium's SEC filings may be accessed electronically by means of the SEC's
home page on the Internet at There may be additional
risks that Auxilium does not presently know or that Auxilium currently
believes are immaterial which could also cause actual results to differ from
those contained in the forward-looking statements.

For More Information, Contact:
James E. Fickenscher / CFO         William Q. Sargent, Jr. /
                                                V.P., IR
Auxilium Pharmaceuticals, Inc.         Auxilium Pharmaceuticals,
(484) 321-5900 (484) 321-5900

SOURCE Auxilium Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.